Immortalization of Osteoclast Precursors by Targeting bcl-XI and Simian Virus 40 Large T Antigen to the Osteoclast Lineage in Transgenic Mice


*Department of Medicine/Hematology; ‡Department of Pathology; ¶Department of Medicine/Endocrinology; University of Texas Health Science Center, San Antonio, Texas 78284; †Department of Periodontology, Maki University, Saitama, Japan; ‡Division of Rheumatology, Deaconess Hospital, Boston, Massachusetts 02215; **Cancer Therapy and Research Center, San Antonio, Texas 78229; and ‡‡Audie Murphy VA Hospital, San Antonio, Texas 78284

Abstract

Cellular and molecular characterization of osteoclasts (OCL) has been extremely difficult since OCL are rare cells, and are difficult to isolate in large numbers. We used the tartrate-resistant acid phosphatase promoter to target the bcl-XI and/or Simian Virus 40 large T antigen (Tag) genes to cells in the OCL lineage in transgenic mice as a means of immortalizing OCL precursors. Immunocytochemical studies confirmed that we had targeted Bcl-XI and/or Tag to OCL, and transformed and mitotic OCL were readily apparent in bones from both Tag and bcl-XI/Tag mice. OCL formation in primary bone marrow cultures from bcl-XI, Tag, or bcl-XI/Tag mice was twofold greater compared with that of nontransgenic littermates. Bone marrow cells from bcl-XI/Tag mice, but not from singly transgenic bcl-XI or Tag mice, have survived in continuous culture for more than a year. These cells form high numbers of bone-resorbing OCL when cultured using standard conditions for inducing OCL formation, with ~50% of the mononuclear cells incorporated into OCL. The OCL that form express calcitonin receptors and contract in response to calcitonin. Studies examining the proliferative capacity and the resistance of OCL precursors from these transgenic mice to apoptosis demonstrated that the increased numbers of OCL precursors in marrow from bcl-XI/Tag mice was due to their increased survival rather than an increased proliferative capacity compared with Tag, bcl-XI, or normal mice. Histomorphometric studies of bones from bcl-XI/Tag mice also confirmed that there were increased numbers of OCL precursors (TRAP + mononuclear cells) present in vivo. These data demonstrate that by targeting both bcl-XI and Tag to cells in the OCL lineage, we have immortalized OCL precursors that form bone-resorbing OCL with an efficiency that is 300–500 times greater than that of normal marrow. (J. Clin. Invest. 1998. 102:88–97.) Key words: osteoclasts • bcl-XI • Simian Virus 40 large T antigen • precursors • transgenic • apoptosis

Introduction

Osteoclasts (OCL)1 are very rare cells in bone, and thus are difficult to isolate in sufficient numbers to characterize them fully at the cellular and molecular level. Immortalization of OCL precursors should greatly enhance our ability to study these parameters by facilitating production of large numbers of OCL in vitro. We previously targeted Simian Virus 40 large T antigen (Tag) to OCL in transgenic mice (TRAP-Tag mice) using the tartrate-resistant acid phosphatase (TRAP) promoter in an attempt to immortalize OCL precursors, but found that this strategy did not immortalize cells in the OCL lineage (1). Mitotic and morphologically transformed OCL developed in these transgenic mice, but OCL apoptosis was also increased, raising the possibility that Tag-induced cell death may have prevented immortalization. These results suggested that expression of an additional gene that could block apoptosis in OCL and their precursors might immortalize OCL precursors in these transgenic mice. Several apoptosis-inhibiting genes have been identified recently, and of these, members of the bcl-2 family are the best characterized (2). Bcl-2 prevents apoptosis induced by a number of agents, and transfection of the bcl-2 gene into hematopoietic precursors blocked apoptosis induced by growth factor withdrawal (3). Bcl-XI is a bcl-2–related gene expressed in a wide range of cell types (4). Like bcl-2, it has been shown to prevent apoptosis both in vivo and in vitro (5–8), and can function as a bcl-2–independent regulator of apoptosis in hematopoietic cells. Therefore, we targeted bcl-XI to cells in the OCL lineage, produced mice doubly transgenic for bcl-XI and Tag, and immortalized OCL precursors from the bcl-XI/Tag mice. These cells form OCL with very high efficiency.

Methods

Construction of the mouse TRAP-bcl-XI hybrid transgene. We have previously described construction of the pBSmTRAPS5 plasmid, which contains 1294 bp of the 5′-flanking sequence, as well as the entire 5′-untranslated region of the murine TRAP gene (9). A plasmid containing the full-length murine bcl-XI cDNA with a 24-bp sequence encoding the FLAG epitope (10) inserted immediately after the AUG initiation codon, was kindly provided by Gabriel Nunez (University of Michigan, Ann Arbor, MI). A 985-bp fragment containing the bcl-XI cDNA was inserted into the unique EcoRI site of

The Journal of Clinical Investigation
Volume 102, Number 1, July 1998, 88–97
http://www.jci.org

88 Hentunen et al.
pBSpKCR3 (11), which contains part of the second exon, the second intron, and the third exon including the polyadenylation site of the rabbit β-globin gene. There are no AUG initiation codons within the β-globin sequences present, so translation of the Bcl-XL protein starts at the normal bcl-XL initiation codon. To generate the mTRAP-bcl-XL hybrid transgene, the mTRAP promoter was cloned immediately upstream of the bcl-XL/globin construct. The transgene was excised by XhoI digestion from the resulting plasmid, TBX6 (Fig. 1), and was agarose gel–purified before microinjection.

**Production and identification of transgenic mice.** The mTRAP-bcl-XL transgene was microinjected at a concentration of 3 μg/ml into the male pronucleus of fertilized one-cell mouse embryos by standard methods (12). The embryos were obtained from mating CB6F1 (C57Bl/6 × BALB/c) males and females (Harlan Sprague Dawley Inc., Indianapolis, IN). The injected embryos were then reimplanted into the oviducts of pseudopregnant B6D2F1, female mice. The presence of the transgene was identified in resulting offspring by Southern blot analysis of DNA (13), which was purified from a small piece of the tail taken at the time the animals were weaned (12). Transgenic mice of subsequent generations were identified by polymerase chain reaction analysis using bcl-XL–specific primers spanning a 416-bp region of the bcl-XL cDNA. Probes for Southern blot analysis were generated by random oligonucleotide labeling (Pharmacia Biotech, Inc., Piscataway, NJ) using [α-32P]dCTP (Dupont-NEB, Boston, MA).

**Northern blot analysis.** Total RNA was extracted from various tissues of transgenic and nontransgenic mice according to the procedure of Chomczynski and Sacchi (14). Northern blot analysis was carried out as described (15) using Nitran membranes and bcl-XL–specific probes generated by random oligonucleotide labeling, as above.

**Assays of osteoclast formation.** Murine bone marrow cells were cultured as described previously (16). In brief, the mice were killed by cervical dislocation, and the tibiae and femora were removed and dissected free from adhering soft tissues. The bone ends were cut off with a scalpel, and the marrow was flushed with α-MEM ( Gibco BRL, Gaithersburg, MD) containing 100 IU/ml penicillin and 100 μg/ml streptomycin ( Gibco BRL). Cells were centrifuged at 1,500 rpm for 10 min, and the pellet was resuspended in 10 ml of α-MEM containing 10% FCS, 2 mM L-mercaptoethanol, and 100 pg/ml of rGM-CSF (R & D Systems, Inc., Minneapolis, MN) and 100 pg/ml of mGM-CSF (R & D Systems, Inc., Minneapolis, MN), and were cultured at 37 °C in a humidified atmosphere of 5% CO2 incubator. Nonadherent cells were collected and centrifuged as previously described (16). Marrow cells (1 × 106/ml) were cultured in 24-well plates for 6 d in the presence of varying concentrations of either 1,25-(OH)2D3 (Dr. M. Uskokovic, Hoffmann-LaRoche, Nutley, NJ) or PTHrP (Bachem Biosciences Inc., King of Prussia, PA). Half of the media was changed every 3 d, and the cultures continued for 7–14 d in α-MEM containing 10% FCS. Therefore, in the standard OCL formation assay, there were ~1,500-3,000 marrow cells/well.

**Effect of serum-free condition on the survival and osteoclast formation capacity of marrow cells from transgenic mice.** Mouse bone marrow cells (106 cells/ml) were suspended in 1.2% methylcellulose (Sigma Chemical Corp.) containing 30% FCS, 1% BSA (Sigma Chemical Corp.), 2.5 × 10−3 M L-mercaptoethanol, and 100 pg/ml of mGM-CSF (R & D Systems, Inc., Minneapolis, MN), and were cultured at 37 °C in a humidified atmosphere of 5% CO2-air in 35-mm petri dishes for 9 d (17) to induce CFU-GM–derived colonies that contain the earliest identifiable OCL precursor. This was done as a means of enriching OCL precursors. CFU-granulocyte macrophage (GM)–derived colonies were isolated individually, and the pooled cells were washed twice with α-MEM, and then plated in 96-well dishes at a cell density of 1,000–2,000 cells/well. These dishes had been plated for 24 h previously with 2,500–5,000 MC3T3-E1 cells/well. We have shown in preliminary experiments that MC3T3-E1 cells support the growth of OCL precursors without inducing terminal differentiation of OCL precursors. After the cocultures reached confluence, they were treated with trypsin/EDTA (JRH Biosciences, Lenexa, KS) for 5 min at 37 °C, and split at the ratio of 1:3. After 2 wk, cultures were transferred into 24-well plates, and, after reaching confluence, were transferred into 6-well plates. The cultures of bcl-XL/Tag cells cocultured on MC3T3-E1 cells have been maintained routinely for more than 18 mo.

**Osteoclast formation assay: coculture with stromal cells.** The OCL formation capacity of bcl-XL/Tag, or bcl-XL/Tag cells that had been cocultured with MC3T3-E1 cells as described above was determined using standard conditions that induce differentiation of OCL precursors to form multinucleated OCL that resorb bone (18). In brief, bcl-XL/Tag, or bcl-XL/Tag cells were cocultured with MC3T3-G2/PA6 stromal cells (1,000 MC3T3-G2/PA6 stromal cells/well in 96-well plates, or 5,000 PA6 cells/well in 48-well plates) that had been plated in the wells on the day before the addition of bcl-XL/Tag, or bcl-XL/Tag cells. Dexamethasone (10−7 M; Sigma Corp., St. Louis, MO) and 1,25-(OH)2D3 (10−9 M) were then added to the cultures, and the cultures continued for 7–14 d in α-MEM containing 10% FCS (18). One tenth of the coculture cells (MC3T3-E1 and marrow cells) from a 24-well plate or 1/20 of the cells from a 6-well plate were pipetted onto the PA6 cells/well. Half of the media was changed every third day. In selected cultures, cells were treated with interleukin-1, or varying concentrations of calcitonin added to cultures of bcl-XL/Tag cells treated with 1,25-(OH)2D3.

To assess the actual number of bcl-XL/Tag, or bcl-XL/Tag marrow cells plated in the assays, we used a cytotoxic antisera that was prepared against mouse fibroblasts (kindly provided by Dr. Yoneda, University of Texas Health Science Center at San Antonio), and that also lysed MC3T3-E1 feeder cells, but not marrow cells, to remove MC3T3-E1 cells before plating on the PA6 cells as follows: MC3T3-E1 cells were completely lysed by incubation with the cytotoxic antisera (1:100 dilution) and rabbit complement (1:50 dilution; Serotec, Oxford, England) for 1 h at 37 °C, as determined by the complete absence of Mac-1–negative cells. Viable marrow cells were then harvested by treatment with trypsin/EDTA for 5 min. The marrow cells were washed with media, and the number of cells was counted. These cells were then cultured with PA6 cells as above to induce OCL formation. After 7 d of culture, the number of OCL-like multinucleated cells, identified by their expression of TRAP and the average number of nuclei in each multinucleated cell, was determined. Our cocultures generally contained ~5–10% marrow cells, and 90–95% feeder cells. Therefore, in the standard OCL formation assay, there were ~1,500-3,000 marrow cells/well.

**Formation of resorption lacunae on dentine slices.** PA6 stromal cells (10,000) were plated on a dentine slice/well in 24-well plates. The following day, 5,000 bcl-XL/Tag cells were added to each culture well, and the cultures were cultured for 7–10 d in α-MEM containing 10% FCS, 2 × 10−5 M 1,25-(OH)2D3, and 10−7 M dexamethasone to induce OCL formation. Half of the media was changed every third day. The cells were fixed and stained for TRAP as described above. After counting TRAP-positive multinucleated cells (MNC), the cells were removed from the dentine slice by brushing, and resorption lacunae were stained with 1% toluidine blue (19). Resorption lacunae on dentine slices were scored by phase contrast microscopy using image analysis software (Bioquant, Nashville, TN) as described previously (17).

**Effect of serum-free condition on the survival and osteoclast formation capacity of marrow cells from transgenic mice.** Murine bone marrow cells obtained from transgenic and nontransgenic littersmates were cultured in 24-well plates (4 × 103 cells) in α-MEM containing 0.1% BSA (CellPro, Inc., Pothell, WA) for 0–96 h at 37 °C in a humidified atmosphere of 5% CO2-air. 20% of the cultures were fixed 24, 48, and 72 h after culture initiation, an aliquot of the cells was obtained, and its viability was assessed by trypan blue exclusion. Then, either 5 × 105 or 1 × 105 viable marrow cells per ml from each time point were cultured in 4-well plates (Nunc, Roskilde, Denmark) for 6 d in α-MEM–10% FCS with 2 × 10−9 M 1,25-(OH)2D3 to assess their capacity to form OCL (16). At the end of this second culture period, the cells were fixed and stained for TRAP activity, as described above.
Osteoclast precursor proliferation. Freshly isolated marrow cells (5 × 10^6/well) from bcl-X<sub>L</sub>/Tag and Tag mice were incubated in 24-well plates in α-MEM containing 0.1% BSA for 24 h. 1 μCi [3H]-thymidine (specific activity 20 Ci/mmol; Dupont NEN, Boston MA) was added. After an additional 48 h of culture, the cells were washed in standard media, and the number of viable cells was counted. 1 × 10<sup>5</sup> viable cells/well were plated in eight-chamber cultures slides (Nunc, Inc. Naperville IL), and 1.25-(OH)<sub>2</sub>D<sub>3</sub> (2 × 10<sup>−9</sup> M) was added. Cells were then cultured in α-MEM containing 10% FCS for 6 d to induce OCL formation. Cells were fixed with 2% glutaraldehyde in PBS for 20 min, and were stained for TRAP as described above. Slides were washed first with water and then with 5% trichloroacetic acid and processed for autoradiography (20).

 Autoradiography and RT-PCR analysis for calcitonin receptor expression. Bcl-X<sub>L</sub>/Tag cells or normal mouse marrow cells were cultured in the presence of 1.25-(OH)<sub>2</sub>D<sub>3</sub> (10<sup>−9</sup> M) and demethasone in 24-well plates as described above. After 7 d of culture, the cells were released with trypsin-EDTA and applied to Labtech chamber slides (Fisher Scientific Co., Pittsburgh, PA). 32<sup>P</sup>-labeled salmon calcitonin (Amersham Corp., Arlington Heights, IL) was added to the slides in the presence or absence of 1 μM of unlabeled calcitonin (Peninsula Laboratories, Inc., Belmont, CA), and the slides were processed as described (17). The percentage of multinucleated cells expressing calcitonin receptors and the relative level of calcitonin receptor expression was compared with that of normal mouse marrow cultures.

To determine which isoform of calcitonin receptor was expressed by bcl-X<sub>L</sub>/Tag cells, equal amounts of RNA (2 μg) from cocultures of bcl-X<sub>L</sub>/Tag cells with MCT3-E1 cells, normal marrow cocultured with PA6 cells, or bcl-X<sub>L</sub>/Tag cells cocultured with MCT3-E1 cells and 1.25-(OH)<sub>2</sub>D<sub>3</sub> (10<sup>−9</sup> M) and demethasone (10<sup>−7</sup> M) were reverse-transcribed into cDNA with a mouse calcitonin receptor (mCTR)-specific primer from the 3′ UTR (5′-GTTGGATCACAATG-CTTGGGTTGGTC-3′) using the Ready-To-Go You-Prime First-Strand Beads kit (Pharmacia Biotech Inc.) that contained cloned FPLCpure MuLV reverse transcriptase, RNase inhibitor, and nucleotides. For the PCR reaction, mCTR primers mT2F (5′-ATCATCATCCACC-3′) and mT3R (5′-CAGAGCATCCAGAGTAGT-3′) were used to generate mCTR PCR products that would include both the C1a (IN:111<sup>−</sup>9) and C1b (IN:111<sup>−</sup>9)-UTR (5′-CTGTTGGAGCAGTCG-3′) using the Ready-To-Go You-Prime First-Strand Beads kit (Pharmacia Biotech Inc.) that contained cloned FPLCpure MuLV reverse transcriptase, RNase inhibitor, and nucleotides. Equal amounts of each cDNA sample (by volume) were added to a total PCR reaction volume of 50 μl containing 10 mM Tris-HCl, pH 8.3, 50 mM KCl, 2.5 mM MgCl<sub>2</sub>, 1 μM each of the 5′ and 3′ primers, 2 μM dNTPs, and 2.5 U Taq DNA polymerase (Fisher Scientific Co., Pittsburgh, PA). PCR conditions were 94°C for 15 s, 55°C for 1 min, and 72°C for 1 min for 40 cycles using Gene Amp PCR system 9600 (Perkin-Elmer Corp., Norwalk, CT). A negative control containing H<sub>2</sub>O instead of cDNA was run with each PCR set. cDNA subclones containing both the mCTR C1a and C1b isoforms were included in the PCR reaction sets as positive controls.

Southern blot analysis of PCR products. PCR products were analyzed by electrophoresis in a 1.8% agarose gel containing TAE buffer, transferred onto nylon membrane (Micron Separation Inc., Westboro, MA) and cross-linked to the filter using Stratalinker<sup>TM</sup> (Stratagene, La Jolla, CA). The filter was prehybridized at 65°C for 2 h in a hybridization solution containing 6× SSPE, 5× Denhardt’s solution, 0.5% SDS, 50 μg/ml denatured DNA, and 10% dextran sulfate. The hybridization was performed at 38°C overnight in hybridization solution containing both the mCTR C1a and C1b isoforms were included in the hybridization solution. The probe was an mCTR primer m2TF+9 (5′-ATGGATCTGGTGCGGCCGGGATC-3′) that does not overlap either m2TF or m3R, end-labeled with [γ-32P]dATP using the T4 kinase (Promega Corp., Madison, WI). The filter was then washed with 2× SSC and 0.1% SDS for 2 h, and autoradiography was performed using an intensifying screen.

Osteoclast apoptosis assay. Murine bone marrow cultures from control and transgenic mice were established as described previously (16). In brief, bone marrow cells were flushed out from the marrow cavity using a 1-ml syringe fitted with a 27-gauge needle, and containing α-MEM. The cells were pelleted by centrifugation, resuspended in α-MEM, and 0.5 × 10<sup>6</sup> cells were plated in 96-well plates. Osteoclast-like multinucleated cells were induced to form during the 7-d culture period by treating the cultures with 10<sup>−8</sup> M 1,25-(OH)<sub>2</sub>D<sub>3</sub>. On day 7, control media or risedenron (10<sup>−7</sup> M), an inducer of osteoclast apoptosis (21), was added to the cultures for 24 h. Cells were then fixed with 3.7% paraformaldehyde in PBS for 10 min, washed briefly with PBS, and stained for TRAP activity and with hematoxylin to visualize the nuclei. The percentage of osteoclasts with pyknotic and/or fragmented nuclei, the classic morphologic features of apoptosis, was scored in quadruplicate cultures with a microscope using a 10× objective as described previously (21).

Processing tissues for histology. Bones (fore and hind limbs, thoracic and lumbar vertebrae) from all animals were fixed in 10% phosphate-buffered formalin for 24–48 h, decalcified in 14% EDTA for 1–3 wk, processed through graded alcohols, and embedded in paraffin wax. Sections (3 μm thick) were cut at various levels from all bones, and were stained with hematoxylin, eosin, orange G, and phloxine. Histomorphometric analysis of cancellous bone volume (amount of bone matrix per cancellous space) and numbers of osteoclasts (including normal, morphologically transformed with enlarged hyperchromatic nuclei, mitotic, and apoptotic per mm<sup>2</sup> bone matrix in the cancellous space) were determined in sections of tibial metaphyses as described previously (1).

Bcl-X<sub>L</sub> antigen immunostaining. Tissue sections were deparaffinized, rehydrated, and washed for 10 min in Tris-buffered saline (TBS), pH 7.3. Sections were given two 15-min treatments with 0.1% H<sub>2</sub>O<sub>2</sub> in methanol. After rinsing, sections were blocked for 1 h with 50% normal rabbit serum in TBS, incubated with the anti-Bcl-X antibody (Transduction Laboratories, Lexington, KY) in dilutions of 1:10–1:200 with TBS, 1% BSA, and 0.02% Tween 20 for 1 h. This was followed by three 5-min washes in TBS with 0.02% Tween 20 (with stirring). The sections were incubated with biotin-conjugated Immunopure rabbit anti-mouse IgG [F(ab′)<sub>2</sub>] (Pierce Chemical Co., Rockford, IL) at a 1:2,000 dilution in TBS, 1% BSA, and 0.02% Tween 20 for 45 min. After three 5-min washes in TBS and 0.02% Tween 20, the sections were incubated in peroxidase-conjugated streptavidin (DAKOPATTS, Copenhagen, Denmark) at a 1:1,500 dilution in TBS, 1% BSA, and 0.02% Tween 20. After three 5-min washes, the sections were treated with DAB (Sigma Chemical Co.), counterstained with methyl green and eosin, and viewed microscopically.

Results

Three transgenic founder mice were generated with the mTRAP-bcl-X<sub>L</sub> transgene shown in Fig. 1, and lines of mice were established from each. Northern blot analysis of tissues from transgenic offspring demonstrated that expression of bcl-X<sub>L</sub> was targeted to bone in each of the three lines of mice. In all mice examined, including both transgenic mice and nontransgenic controls, bcl-X<sub>L</sub> mRNA was most abundant in the brain, thymus, and kidney. However, only in transgenic mice could bcl-X<sub>L</sub> mRNA be detected in long bone and calvaria (Fig. 2). A low level of expression was also detected in the brown fat of transgenic mice, consistent with the pattern of tissue-specific expression we previously observed with the murine TRAP promoter (9). The highest level of bcl-X<sub>L</sub> expression in the bone was observed in the mTRAP-bcl-X<sub>L</sub> line 2, and therefore, most of the subsequent analyses and interbreeding to mTRAP-Tag mice to generate bcl-X<sub>L</sub>/Tag doubly transgenic mice was performed with mice of this line.

Immunohistochemical analysis confirmed that we had targeted expression of bcl-X<sub>L</sub> to osteoclasts. Bcl-X<sub>L</sub> was not detectable in osteoclasts from nontransgenic littermates (Fig. 3A), but was detected in osteoclasts from both bcl-X<sub>L</sub> (Fig. 3B) and...
bcl-X<sub>L</sub>/Tag doubly transgenic mice (Fig. 3 C). Surprisingly, the level of Bcl-X<sub>L</sub> in osteoclasts of bcl-X<sub>L</sub> mice appeared to be lower than in bcl-X<sub>L</sub>/Tag mice (as assessed by the strength of the signal at similar dilutions of the anti-Bcl-X antibody) for reasons that are unclear.

Bone sections from bcl-X<sub>L</sub> transgenic mice showed normal histology (Fig. 3 D) and normal osteoclasts (Fig. 3 E) when examined at 3 wk, 3 mo, and 6 mo of age, and they never developed osteopetrosis, as determined radiologically and histologically. In contrast, some of the mice transgenic for either Tag or bcl-X<sub>L</sub>/Tag had developed mild osteopetrosis when killed at the age of 2–4 mo. In addition, transformed osteoclasts were readily apparent in both Tag and bcl-X<sub>L</sub>/Tag mice (Fig. 3 F). In bcl-X<sub>L</sub>/Tag mice, 62% of osteoclasts appeared to be transformed, and 3% were mitotic (Table I). In mice transgenic for Tag alone, these numbers were 57% and 2%, respectively. In both lines, the numbers of apoptotic osteoclasts were similarly increased (Tag: 7%, bcl-X<sub>L</sub>/Tag: 6%) compared with either control littersates (0%) or bcl-X<sub>L</sub> mice (0%). Osteoclast numbers/mm<sup>2</sup> bone area in tibial metaphyseal cancellous bone were not significantly different in bcl-X<sub>L</sub>, bcl-X<sub>L</sub>/Tag, or Tag mice compared with nontransgenic littersmates. However, higher numbers of osteoclasts/mm<sup>2</sup> bone area were observed in the femurs of transgenic mice, with 391±55 in Tag mice and 528±110 in bcl-X<sub>L</sub>/Tag mice vs. 232±60 in control mice (Table I). In addition, the number of TRAP-positive mononuclear cells was significantly increased in bcl-X<sub>L</sub>/Tag mice in comparison with Tag mice (Fig. 3 G and Table II).

We next examined the capacity of marrow obtained from the various classes of transgenic mice to form OCL in response to 1,25-(OH)<sub>2</sub>D<sub>3</sub> (10<sup>-10</sup> to 10<sup>-7</sup> M) and PTHrP (0.1 ng/ml to 1 g/ml) in cultures, as a means of assessing the sensitivity of OCL precursors from these transgenic mice to these osteotropic factors and the relative number of OCL precursors present in marrow from these mice. Osteoclast formation in response to varying concentrations of 1,25-(OH)<sub>2</sub>D<sub>3</sub> or PTHrP showed similar dose-response patterns compared with nontransgenic controls (Fig. 4, A and B). However, the numbers of osteoclasts formed in the primary marrow cultures from transgenic mice were significantly increased compared with their normal littersmates. For example, marrow cells from mice transgenic for either bcl-X<sub>L</sub>, Tag, or bcl-X<sub>L</sub>/Tag formed two times more osteoclasts per 10<sup>6</sup> marrow cells plated in response to 10<sup>-9</sup> M 1,25-(OH)<sub>2</sub>D<sub>3</sub> than did control marrow cultures (Fig. 4 A), demonstrating that OCL precursors were increased in marrow samples from the transgenic mice. Osteoclast formation was increased to a similar extent in all 3 bcl-X<sub>L</sub> mouse lines (data not shown).

Marrow cells derived from these transgenic mice also showed distinct differences in their capacity to be passaged. Normal cells survived less than a month, and 0.15% of cells formed osteoclasts at that time. Marrow cells obtained from either Tag or bcl-X<sub>L</sub> transgenic mice survived for 2–4 mo, and formed few osteoclasts at that time. In contrast, marrow cells

### Table I. Histomorphometry of Transgenic Mouse Bones

<table>
<thead>
<tr>
<th>Group</th>
<th>TRAP+ mono. cells/marrow</th>
<th>No. of OCL in tibiae/mm&lt;sup&gt;2&lt;/sup&gt;</th>
<th>Transformed OCL</th>
<th>Mitotic OCL</th>
<th>Apoptotic OCL</th>
</tr>
</thead>
<tbody>
<tr>
<td>Control</td>
<td>0.73±0.13</td>
<td>163±52</td>
<td>0</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>bcl-X&lt;sub&gt;L&lt;/sub&gt;</td>
<td>0.24±0.04</td>
<td>220±157</td>
<td>0</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>Tag</td>
<td>9.40±5.77</td>
<td>172±49</td>
<td>57±7</td>
<td>2±1</td>
<td>7±2</td>
</tr>
<tr>
<td>bcl-X&lt;sub&gt;L&lt;/sub&gt;/Tag</td>
<td>35.88±5.46*</td>
<td>228±104</td>
<td>62±11</td>
<td>3±1</td>
<td>6±3</td>
</tr>
</tbody>
</table>

Histomorphometric analysis of decalcified mouse bone was performed as described in Methods. The number of TRAP+ mononuclear cells was significantly increased in bcl-X<sub>L</sub>/Tag mice when compared with Tag mice (P < 0.016).

### Table II. Survival of Primary Marrow Cells from Transgenic Mice in Continuous Cultures

<table>
<thead>
<tr>
<th>Source of marrow</th>
<th>Survival in vitro</th>
<th>Cells incorporated into OCL</th>
</tr>
</thead>
<tbody>
<tr>
<td>Normal</td>
<td>&lt; 1 mo</td>
<td>0.15</td>
</tr>
<tr>
<td>bcl-X&lt;sub&gt;L&lt;/sub&gt;</td>
<td>~ 2 mo</td>
<td>~ 0</td>
</tr>
<tr>
<td>Tag</td>
<td>~ 4 mo</td>
<td>0.36</td>
</tr>
<tr>
<td>bcl-X&lt;sub&gt;L&lt;/sub&gt;/Tag</td>
<td>&gt; 18 mo</td>
<td>30–50</td>
</tr>
</tbody>
</table>

Marrow cells from control and transgenic mice were cultured with MC3T3-E1 cells as described in Methods. Aliquots of the cultures were assessed at the time indicated for their capacity to form OCL. The percentage of cells incorporated into OCL was determined by counting the average number of nuclei per 100 OCL, multiplying this number by the number of OCL formed, and dividing the product by the number of cells originally plated.
Figure 3. (A–C) Immunostaining for Bcl-Xl in decalcified sections of proximal tibiae. (A) A moderately strong signal for Bcl-Xl is seen in the cytoplasm of a megakaryocyte (arrowhead) in the bone marrow of this normal littermate of Bcl-Xl transgenic mice, but no signal is seen in the cytoplasm of osteoclasts (arrow) on the bone surface in the primary spongiosa. Primary antibody dilution, 1/50; hematoxylin and eosin (H & E) counterstain; original magnification 100×. (B) A strong signal for Bcl-Xl is seen in the cytoplasm of osteoclasts (arrows) along the bone surface in a bcl-Xl transgenic mouse. Primary antibody dilution, 1/25; H & E counterstain; original magnification 100×. (C) A stronger signal for Bcl-Xl...
Table III. Effects of IL-1, 1,25-(OH)2D3, Calcitonin, and Dexamethasone on MNC Formation by bel-XL/Tag Cells

<table>
<thead>
<tr>
<th>Treatment</th>
<th>MNC/2,000 Bcl/Tag/ cells plated</th>
</tr>
</thead>
<tbody>
<tr>
<td>Control</td>
<td>1.3±0.3</td>
</tr>
<tr>
<td>1,25-(OH)2D3 (10^−9 M)</td>
<td>25.3±5.9</td>
</tr>
<tr>
<td>1,25-(OH)2D3 + calcitonin (50 ng/ml)</td>
<td>13.8±1.0</td>
</tr>
<tr>
<td>Dexamethasone (10^−6 M)</td>
<td>6.8±0.8</td>
</tr>
<tr>
<td>1,25-(OH)2D3 + dexamethasone</td>
<td>201.5±11.2</td>
</tr>
<tr>
<td>IL-1β (10 ng/ml)</td>
<td>8.5±0.6</td>
</tr>
</tbody>
</table>

Bcl-XL/Tag cells (2,000 cells/well) were cultured with PA6 cells in the presence of varying concentrations of IL-1 (10 ng/ml), salmon calcitonin (50 ng/ml), dexamethasone (10^−6 M), or 1,25-(OH)2D3 (10^−6 M) for 7 d. The cultures were fixed, and the number of TRAP-positive MNC was scored. MNC contained 6±1 nuclei per cell. Results represent the mean±SEM for four determinations from a typical experiment. *p < 0.05 compared to control. ‡p < 0.05 compared to control. §p < 0.001 compared to control.

Fig. 3 H, Fig. 5), reflecting the increased survival of OCL precursors compared with nonosteoclastic marrow cells in these cultures with passage. This enhanced survival of OCL precursors resulted in enrichment of OCL precursors as the cells were passaged. Treatment of cultures of passaged bcl-XL/Tag cells with 1,25-(OH)2D3 demonstrated that they formed large numbers of OCL, and that calcitonin markedly inhibited OCL formation by these cells (Table III). Furthermore, IL-1 modestly enhanced formation of OCL by bcl-XL/Tag cells (Table III).

RT-PCR and Southern blot analyses of the PCR products demonstrated that bcl-XL/Tag cells did not express calcitonin receptors unless they were stimulated with 1,25-(OH)2D3. Both bcl-XL/Tag cells and normal mouse marrow cells cultured with 1,25-(OH)2D3 expressed the C1a isoform of calcitonin receptor. None of these cultures expressed the C1b isoform of calcitonin receptor (Fig. 6). Autoradiographic studies demonstrated that > 95% of MNC formed by bcl-XL/Tag cells expressed calcitonin receptor at levels similar to MNC formed in marrow cultures from normal mice (Fig. 7, A–C).

When primary bone marrow cells obtained from the various classes of transgenic mice or nontransgenic littermates were preincubated in α-MEM without serum for varying periods of time, the viability of the total marrow cells present was decreased over time in a similar manner (data not shown).

Figure 3 legend (Continued)

is seen in the cytoplasm of osteoclasts (arrows) in the bcl-XL/Tag doubly transgenic mouse than in the cytoplasm of osteoclasts in bcl-XL transgenic mice despite a doubling of the primary antibody dilution (1/50). Note also the larger size of the osteoclasts in these mice (F). H & E counterstain; original magnification 100×. (D and E) Proximal humerus of a 6-wk-old bcl-XL transgenic mouse. (D) The appearances of the epiphysis, metaphysis, and cortical bone are indistinguishable from those of normal littermates. H & E; original magnification 6.5×. (E) Osteoclasts (arrows) at the epiphysial plate appear normal, and have several nuclei with regular shape and size. H & E; original magnification 100×. (F) Osteoclasts in a bcl-XL/Tag doubly transgenic mouse. Morphologically transformed (i.e., having enlarged nuclei with dense irregular chromatin and multiple large nucleoli; thick arrow), mitotic (arrowhead), and apoptotic (thin arrow) osteoclasts similar to those reported previously in Tag transgenic mice (1) are present on the bone surface of this 6-wk-old mouse. H & E; original magnification 100×. (G) TRAP-stained section of proximal humerus of a bcl-XL/Tag doubly transgenic mouse. TRAP-positive osteoclasts are seen adjacent to bone surfaces near the epiphysial plate of an 8-wk-old mouse. Sheets of TRAP-positive mononuclear cells (arrows) have replaced normal hematopoietic cells in parts of the section. Hematoxylin counterstain; original magnification 50×. (H) TRAP staining of cultured bcl-XL/Tag cells. Bcl-XL cells were cultured in the presence of PA6 stromal cells, 1,25-(OH)2D3 and dexamethasone for 1 wk. Numerous TRAP-positive multinucleated cells (arrow), some with intense staining (arrowhead), and TRAP-positive mononucleated cells are present. Original magnification 200×.
Figure 5. Formation of resorption lacunae by MNC formed by bcl-XL/Tag cells cocultured with 1,25-(OH)2D3 and dexamethasone on PA6 cells. Magnification 50×.

However, osteoclast precursor survival showed distinct differences after prolonged exposure to serum-free conditions. The number of OCL formed by nontransgenic marrow mononuclear cells preincubated in serum-free conditions decreased steadily, and was 2.4% of the initial value after 96 h of serum-free preculture (Fig. 8). In contrast, marrow cells from bcl-XL mice after 48 h of serum-free preculture retained their capacity to form OCL, but then began progressively to lose this capacity. OCL formation in cultures of bcl-XL marrow that were preincubated in serum-free conditions was modestly better than results with nontransgenic marrow cultures. OCL formation in cultures of Tag marrow cells preincubated for up to 48 h in serum-free conditions initially increased, but after 96 h of serum-free preculture, was decreased by 32% compared with the initial value. In contrast, the relative proportion of osteoclast precursors in the viable marrow cells remaining from bcl-XL/Tag mice after 96 h of preincubation increased sixfold compared with the initial value (Fig. 8).

To determine if the increased OCL formation capacity of bcl-XL/Tag marrow cells in serum-free cultures was due to resistance to apoptosis vs. increased proliferation of the marrow cells, marrow cells from bcl-XL/Tag mice were labeled with [3H]thymidine, preincubated for 48 h in serum-free media, and then assayed for their capacity to form OCL. Approximately 2% of the nuclei in the OCL formed in bcl-XL/Tag cultures were labeled, as compared with 4% for Tag mice, indicating that an increase in proliferation did not account for the increased numbers of OCL formed in bcl-XL/Tag cultures.

To determine if the survival advantage seen in OCL precursors from bcl-XL/Tag mice was also conferred to multinucleated OCL formed from those precursors, the percentage of mature OCL undergoing apoptosis in marrow cultures from these transgenic mice was then determined. Based on the morphology and nuclear fragmentation patterns in OCL formed in the cultures, no differences were detected in the percentage of apoptotic OCL under basal conditions between control and transgenic mice of the various classes (control, 31±9%; bcl-XL, 29±7%; Tag, 32±5%; bcl-XL/Tag, 31±4%).

Discussion

Targeting bcl-XL and Tag to cells in the OCL lineage allowed us to immortalize OCL precursors that can form OCL at high efficiency. Tissue-specific targeting of SV40 Tag expression in transgenic mice has been used to transform many cell types, permitting the establishment of a variety of novel cell lines (22–25). Before our current studies, immortalized OCL precursors that form OCL at high efficiency and resorb bone had not been described. We previously targeted Tag expression to OCL of transgenic mice using the murine TRAP promoter (1). While mTRAP-Tag transgenic mice exhibited mitotic and transformed OCL, we were unsuccessful in immortalizing OCL precursors from the bone marrow of these mice (1). Because we observed a significant number of apoptotic OCL in the bones of these mice, we postulated that Tag expression had induced apoptosis concomitantly with the transformation of OCL. High levels of apoptosis have also been observed in other Tag-expressing cell types in transgenic mice (26–28), despite presumptive inactivation of p53 by Tag. We therefore thought that introducing an apoptosis-inhibiting gene might block Tag-induced apoptosis, and permit immortalization of OCL precursors. To this end, we generated mTRAP-bcl-XL transgenic mice, and interbred these mice to the mTRAP-Tag mice to create bcl-XL/Tag doubly transgenic mice. Immunohistochemical and histomorphometrical analyses confirmed that we had targeted bcl-XL to OCL, and that the bcl-XL/Tag and Tag mice had mitotic and transformed OCL.

Culture studies of marrow from the various transgenic cell lines demonstrated that targeting bcl-XL and/or Tag to cells in the OCL lineage increased the number of OCL precursors. Marrow cells from TRAP-Tag, TRAP-bcl-XL, and TRAP-bcl-XL/Tag transgenic mice formed two times more osteoclasts in the presence of 10−8 M 1,25-(OH)2D3 compared with control mouse marrow cells, even though the sensitivity of marrow cells from TRAP-Tag, TRAP-bcl-XL or TRAP-Tag/bcl-XL mice to either 1,25-(OH)2D3 or PThrP did not differ from nontransgenic littermate controls.
However, expression of \( bcl-X_L \) and Tag together, rather than either alone, enhanced survival of OCL precursors. Culture of transgenic marrow cells from these different transgenic mouse strains in serum-free conditions, to deprive the cells of growth factors, demonstrated that OCL precursors from \( bcl-X_L/Tag \) mice persisted longer in vitro than OCL precursors from \( bcl-X_L \) and Tag mice. This survival advantage was not conferred to the total marrow cell population, but only to the OCL precursor subpopulation, since total marrow cell numbers from transgenic mice and control mice decreased in serum-free media at the same rate. OCL precursors are a very small subpopulation of total marrow cells (~0.15%), and differences in viability of this subpopulation would not be readily apparent by simply measuring total cell viability. However, when OCL precursors were assayed by their capacity to form OCL, we found that OCL precursors in \( bcl-X_L/Tag \) marrow cells were progressively enriched after 96 h of serum-free preincubation. In contrast, significantly fewer OCL precursors survived in serum-free cultures of marrow cells from \( bcl-X_L \), Tag, or control mice after 96 h.

Targeting the antiapoptotic \( bcl-X_L \) gene to OCL by itself did not have a major effect on the survival of osteoclast precursor cells when cocultured with osteoblastic cells. Instead of 1 mo (survival of control marrow cells), OCL precursors from \( bcl-X_L \) marrow survived for ~2 mo in continuous culture. Tag alone was clearly superior in its capacity to enhance survival of OCL precursors compared with \( bcl-X_L \), since these cells survived for 4 mo. However, when both Tag and \( bcl-X_L \) were targeted to cells in the OCL lineage, the resulting OCL precursors had a greatly increased survival capacity. Cells from the doubly transgenic mice have now been continuously cultured for more than 18 mo, and they continue to form OCL that resorb bone. This enhanced survival capacity of OCL precursors from \( bcl-X_L/Tag \) mice compared with other marrow cell types resulted in progressive enrichment of OCL precursors as the marrow cells were passaged.

Histomorphometry demonstrated that \( bcl-X_L/Tag \) mice had significantly more TRAP-positive mononuclear cells compared with nontransgenic littermates, Tag mice, or \( bcl-X_L \) mice, consistent with our in vitro findings of increased OCL precursor numbers and survival in \( bcl-X_L/Tag \) mice. Since TRAP is an in vivo marker enzyme for cells in the OCL lineage, these data suggest that OCL precursors were increased in \( bcl-X_L/Tag \) mice in vivo. OCL numbers in vivo in transgenic mouse bones and control mouse bone were about the same, suggesting that OCL in \( bcl-X_L \) and \( bcl-X_L/Tag \) mice do not live longer than OCL in nontransgenic littermates or in Tag mice, and that the survival advantage of \( bcl-X_L/Tag \) genes occurs predominantly at the OCL precursor stage of differentiation. These data were consistent with our in vitro OCL apoptosis assay. In all our three transgenic mouse lines and in nontransgenic littermates, the percentage of OCL undergoing apoptosis in marrow cultures was ~30%, and was increased to 50-

![Figure 7. Autoradiography of MNC formed by \( bcl-X_L/Tag \) cells in the presence of 1,25-(OH)\(_2\)D\(_3\) demonstrated that they express calcitonin receptors (A), and that binding of \([125I]\)salmon calcitonin to the MNC was competed by excess unlabeled calcitonin (B). Similar levels of expression for calcitonin receptors were detected in multinucleated cells formed from normal mouse marrow cultures (C).](image-url)

![Figure 8. OCL formation capacity of OCL precursors obtained from transgenic mice in serum-free culture for up to 96 h.](image-url)
60% by adding $10^{-5}$ M risedronate in a similar manner in all these groups.

The OCL formation capacity of bcl-XI/Tag cells is approximately 300–500 times higher than that of normal mouse marrow, with 30–50% of bcl-XI/Tag cells being incorporated into OCL when cocultured with PA6 cells and $10^{-7}$ M dexamethasone and $10^{-5}$ M 1,25-(OH)$_2$D$_3$, and appears superior to previously reported OCL precursor cell lines developed from murine sources. The MNC, which were generated in these cultures, formed resorption lacunae on dentine, and also expressed the C1a isoform of the calcitonin receptor. The C1a isoform of the calcitonin receptor is the predominant isoform of the receptor expressed in murine osteoclasts (29). Additionally, the MNC that formed expressed calcitonin receptors at similar levels as normal marrow cells. Further, calcitonin inhibited OCL formation by bcl-XI/Tag cells to a similar degree as normal marrow cells. Takahashi and coworkers (16) reported that calcitonin inhibited OCL by normal marrow cultures by $\sim$50%. Hence, the MNC express the characteristics of OCL. However, preliminary experiments suggest that bcl-XI/Tag cells respond differently to some osteotropic factors than do normal marrow cells. For example, IL-1 is not a potent stimulator of OCL formation by bcl-XI/Tag cells, and prostaglandin E2 does not induce OCL formation by bcl-XI/Tag cells.

Chambers and coworkers (30) also developed OCL precursor cell lines from mice transgenic for temperature-sensitive Tag driven by interferon-inducible MHC complex H-2Kb promoter. The initial OCL formation capacity of these cell lines was 2.5% (Chambers, personal communications). However, the MNC expressed the characteristics of OCL. Moreover, preliminary experiments suggest that bcl-XI/Tag cells respond differently to some osteotropic factors than do normal marrow cells. For example, IL-1 is not a potent stimulator of OCL formation by bcl-XI/Tag cells, and prostaglandin E2 does not induce OCL formation by bcl-XI/Tag cells.

**Acknowledgments**

The authors wish to acknowledge the Academy of Finland for funding this research.

**References**


sis during the transition from preneoplasia to carcinoma. *Cancer Res.* 56:2998–3003.
Moseley, and D.M. Findlay. 1995. Calcitonin receptor isoforms in mouse and
1993. Generation of osteoclast-inductive and osteoclastogenic cell lines from
31. Hagenaars, C.E., A.A.M. van der Kraan, E.W.M. Kavilarang-deHaas,
J.W.M. Visser, and P.J. Nijweide. 1989. Osteoclast formation from cloned pluri-
hemopoietic cells and a multipotential cell line in vitro. *J. Cell. Physiol.* 140:
478–482.
vitro differentiation of the murine macrophage cell line BDM-1 into osteoclast-